Oncology Pharmacy Clinical Sessions (Cert # L249225)

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

• Targeted therapy options in hormone receptor-positive (HR+), early-stage breast cancer.
• Integration of PARP inhibitors into treatment of breast, prostate, ovarian, and pancreatic cancers

Board certified pharmacists are eligible to receive up to 4 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP is approved by BPS as a provider for the recertification of BCOP.

Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer
ACPE: 0217-9999-24-067-H01-P

• Apply recent literature surrounding targeted therapy options in hormone receptor-positive (HR+), early-stage breast cancer.
• Identify characteristics of early-stage HR+ breast cancer patients most likely to benefit from targeted adjuvant therapy.
• Analyze literature regarding the integration of oral selective estrogen receptor degraders into current treatment guidelines.
• Recommend appropriate treatment strategies for patients who qualify to receive inhibitors of the PI3K/AKT pathway.
• Evaluate targeted treatment options beyond endocrine therapy for HR+ metastatic breast cancer. 

This activity is approved for Board-Certified Oncology Pharmacist (BCOP) recertification credit. 

Secondary School: Risk and Management of Secondary Malignancies in the Era of Targeted Therapy
ACPE: 0217-9999-24-068-H01-P

• Assess clinical data evaluating the integration of PARP inhibitors into the treatment of breast, prostate, ovarian, and pancreatic cancers.
• Identify patients who are appropriate for initiation of PARP inhibitor therapy.
• Describe the pathophysiology, incidence, and risk factors of PARP inhibitor-associated secondary myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
• Summarize treatment paradigm changes with the updated classification of MDS and AML.
• Design a treatment strategy for patients with MDS or AML with previous PARP inhibitor exposure. 

This activity is approved for Board-Certified Oncology Pharmacist (BCOP) recertification credit.

Faculty bios

Farah Raheem, PharmD, BCOP 
Clinical Oncology Pharmacist, Hematology/Oncology
Mayo Clinic 

Erin L. H. Zacholski, PharmD, BCOP
Assistant Professor
Virginia Commonwealth University School of Pharmacy 

Kyle Zacholski, PharmD, BCOP  
Clinical Pharmacy Specialist, Hematology & Oncology
VCU Health 

Julia L. Ziegengeist, PharmD, BCOP
Clinical Pharmacist Coordinator, Breast Solid Tumor Oncology
Levine Cancer Institute, Atrium Health    

Angela Cassano, PharmD, BCPS
Kristi Hofer, PharmD
Amy Holmes, PharmD, BCPPS

Janet Bramell, PharmD, BCPS, BCOP
Jasmin Eugene, PharmD, BCOP
Sarah Jane Faro, PharmD, BCPS, BCOP
Tsion Gebru, PharmD, BCOP
Baher Ghanem, BSc, Pharm
Rene Gonzalez, PharmD, BCPS, BCOP
Katherine Hill, PharmD, BCOP
Elle Kim, RPh, BCPS, BCOP
Pohung Lin, PharmD, BCOP, BCPS
Linda Linderbeck, PharmD, BCOP
Annie Pellegrino, PharmD, BCOP
Tashrique Rahman, PharmD, MBA, BCOP
Emma Sheldon, PharmD, BCOP
Berenice Sheridan, BPharm (Hons), BCOP
Barbara Yim, PharmD, BCOP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

• Farah Raheem: Advisory board, AstraZeneca; Advisory board, Lilly
• Erin Zacholski: Speaker, Internal Medical Affairs – Seagen; Advisory Board Member, UroGen

Activities consist of audio/video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

ACCP and ASHP collaborate on oncology pharmacy activities.